I think everyone here should note that the list ra
Post# of 15624
(Total Views: 454)
Posted On: 03/31/2017 7:29:29 PM
I think everyone here should note that the list ranked the companies in what is the proper way, not alphabetically, or by share price, nor did they rank the stocks by what exchange they were on. No, they ranked the stocks by their market cap's and that's really what it's all about. We ranked seventh on the list, though many of the stocks below us are on more major exchanges.
People here need to stop referring to us as a Pink stock, we're not, we're on the OTC which is noted on the list as OTCQB, Pink stocks are noted as OTCPK on the list.
Looking at the list, only GWPH has a market cap in the billions. If we were to hit a price of roughly $5, and the companies above us didn't move up dramatically, we could be in second position by the third quarter if we're successful in beginning sales by then. In fact, I think it's very possible that with sales we could become the second stock on the list to reach the billion dollar market cap, i.e. roughly $7.
I believe we'll move up in a series of steps, probably starting with the Annual Report which should give us an updated forecast by the company of their goals for the year, and perhaps give us a greater understanding of the trials to date.
Additional steps will largely come on the announcement of various trial results, I believe that we can expect to learn more on at least a few of the companies products in the next 3 months, this should culminate in the results for the psoriasis cream safety trial which is being reviewed by the FDA as well as Israeli authorities. The final step in the next quarter, or early in the third quarter would be sales of one or more of the companies products.
Frankly, while we've heard far more about the psoriasis cream, the company speaks about the sublingual tablet as if it too could be in sales at roughly the same time. I'd like to hear more about what testing on this product is, but perhaps only limited testing is needed for sales in Green Cross stores, and it may nearly be completed.
Should we achieve having both drugs in sales by the end of the third quarter, I believe that by the end of the year we could overtake GWPH, and depending on sales volume, the $35 predicted by many here is not out of the question.
Of course all the above has us moving up, while others essentially stand still, that probably won't happen. Other's will move up as well, but if we're the one with sales, and others aren't, we still should overtake them.
Gary
People here need to stop referring to us as a Pink stock, we're not, we're on the OTC which is noted on the list as OTCQB, Pink stocks are noted as OTCPK on the list.
Looking at the list, only GWPH has a market cap in the billions. If we were to hit a price of roughly $5, and the companies above us didn't move up dramatically, we could be in second position by the third quarter if we're successful in beginning sales by then. In fact, I think it's very possible that with sales we could become the second stock on the list to reach the billion dollar market cap, i.e. roughly $7.
I believe we'll move up in a series of steps, probably starting with the Annual Report which should give us an updated forecast by the company of their goals for the year, and perhaps give us a greater understanding of the trials to date.
Additional steps will largely come on the announcement of various trial results, I believe that we can expect to learn more on at least a few of the companies products in the next 3 months, this should culminate in the results for the psoriasis cream safety trial which is being reviewed by the FDA as well as Israeli authorities. The final step in the next quarter, or early in the third quarter would be sales of one or more of the companies products.
Frankly, while we've heard far more about the psoriasis cream, the company speaks about the sublingual tablet as if it too could be in sales at roughly the same time. I'd like to hear more about what testing on this product is, but perhaps only limited testing is needed for sales in Green Cross stores, and it may nearly be completed.
Should we achieve having both drugs in sales by the end of the third quarter, I believe that by the end of the year we could overtake GWPH, and depending on sales volume, the $35 predicted by many here is not out of the question.
Of course all the above has us moving up, while others essentially stand still, that probably won't happen. Other's will move up as well, but if we're the one with sales, and others aren't, we still should overtake them.
Gary
(5)
(0)